KIRhub 2.0
Sign inResearch Use Only

RAF1

Sign in to save this workspace

UniProt P04049 · PDB · AlphaFold · Substrate: MEK1 (K97R) · Clone: catalytic (aa306-648)

Top inhibitors

#DrugInhibitionResidualKISSGini
1Apatinib100.0%0.0%97.730.704
2Ponatinib100.0%0.0%78.230.534
3Ripretinib100.0%0.0%92.950.674
4Sorafenib100.0%0.0%96.720.776
5Regorafenib99.9%0.1%95.990.719
6Upadacitinib99.9%0.1%97.980.663
7Umbralisib99.8%0.2%98.740.670
8Dabrafenib99.8%0.2%94.740.633
9Encorafenib99.7%0.3%98.500.755
10Nilotinib98.3%1.7%96.490.765
11Rabusertib95.6%4.4%98.740.687
12Pazopanib95.5%4.5%97.490.672
13Vemurafenib95.2%4.8%96.490.598
14Dasatinib74.3%25.7%87.970.699
15Imatinib74.0%26.0%99.000.718
16Tivozanib67.6%32.4%92.420.673
17Erdafitinib61.4%38.6%95.710.737
18Paxalisib54.2%45.8%99.750.609
19Repotrectinib51.6%48.4%84.210.608
20Ibrutinib37.5%62.5%94.740.723

Paralog block

ARAF, BRAF, RAF1

ARAFBRAFRAF1

EMT expression

  • Mesenchymal log2(TPM+1): 5.79
  • Epithelial log2(TPM+1): 5.52
  • Fold change: 0.27
  • Status: No significant change

Selectivity landscape vs inhibition on RAF1

Each point is one of the 92 approved drugs; color = inhibition % on RAF1.

Mutation lollipop

Cancer-associated mutations plotted by residue position. Marker size + color scale with the number of distinct cancer reports.

Variants (1)

Mutation × cancer associations

MutationCancerOrganSource
R391Wcarcinoid-endocrine_tumour_lungLungref
R391Wlymphoid_neoplasm_haematopoietic_and_lymphoid_tissueBlood/Lymphatic Systemref
R391Wmalignant_melanoma_skinSkinref
R391WCLLE-ESBlood/Lymphatic Systemref
R391WKIRP-USKidneyref
R391WKIRPKidneyref

3D structure

Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.

Annotations

Sign in to read and post annotations.

Loading…